A Hope for Curing Psoriasis
BIOCAD developed an original Russian drug based on monoclonal antibodies, blocking interleukin-17. That novel drug will help cure severe psoriasis. Soon the company will start phase II clinical trial program – the next to the last stage of drug development before marketing authorization and launch of the new product.
Local development of a drug for psoriasis will positively impact the tactics of treatment of patients with psoriasis and psoriatic arthritis, will improve outcomes, lower the risk of disability and help bring patients back to normal life. It should also be noted, that development and use of such drugs will form conditions for a large-scale implementation of standard approaches to assessment of effectiveness and safety of genetically engineered biological drugs, will improve access to medical aid and decrease dependence on foreign drugs with similar mode of action.
The drug is expected to be launched in 2020.